# Resideo Technologies, Inc.: financial statements, quarterly

REZI · NYSE · CIK 1740332 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rezi.md) · [Financials](/companies/rezi/financials.md) · [Filings](/companies/rezi/filings.md) · [Insiders](/companies/rezi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rezi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,554](/filings/0001740332-24-000059.md) | [1,537 d](/filings/0001740332-26-000005.md) | [1,486](/filings/0001740332-25-000019.md) | [1,589](/filings/0001740332-25-000024.md) | [1,828](/filings/0001740332-25-000034.md) | [1,858 d](/filings/0001740332-26-000005.md) | [1,770](/filings/0001740332-26-000018.md) | [1,943](/filings/0001740332-26-000025.md) | [1,864](/filings/0001740332-25-000034.md) | [1,895 d](/filings/0001740332-26-000005.md) | [1,912](/filings/0001740332-26-000018.md) | [1,981](/filings/0001740332-26-000025.md) |
| Cost of revenue | $m | [1,137](/filings/0001740332-24-000059.md) | [1,114 d](/filings/0001740332-26-000005.md) | [1,086](/filings/0001740332-25-000019.md) | [1,142](/filings/0001740332-25-000024.md) | [1,304](/filings/0001740332-25-000034.md) | [1,328 d](/filings/0001740332-26-000005.md) | [1,259](/filings/0001740332-26-000018.md) | [1,374](/filings/0001740332-26-000025.md) | [1,308](/filings/0001740332-25-000034.md) | [1,335 d](/filings/0001740332-26-000005.md) | [1,361](/filings/0001740332-26-000018.md) | [1,386](/filings/0001740332-26-000025.md) |
| Gross profit | $m | [417](/filings/0001740332-24-000059.md) | [423 d](/filings/0001740332-26-000005.md) | [400](/filings/0001740332-25-000019.md) | [447](/filings/0001740332-25-000024.md) | [524](/filings/0001740332-25-000034.md) | [530 d](/filings/0001740332-26-000005.md) | [511](/filings/0001740332-26-000018.md) | [569](/filings/0001740332-26-000025.md) | [556](/filings/0001740332-25-000034.md) | [560 d](/filings/0001740332-26-000005.md) | [551](/filings/0001740332-26-000018.md) | [595](/filings/0001740332-26-000025.md) |
| Research and development | $m | [28.0](/filings/0001740332-24-000059.md) | [25.0 d](/filings/0001740332-26-000005.md) | [25.0](/filings/0001740332-25-000019.md) | [21.0](/filings/0001740332-25-000024.md) | [23.0](/filings/0001740332-25-000034.md) | [42.0 d](/filings/0001740332-26-000005.md) | [35.0](/filings/0001740332-26-000018.md) | [41.0](/filings/0001740332-26-000025.md) | [44.0](/filings/0001740332-25-000034.md) | [47.0 d](/filings/0001740332-26-000005.md) | [48.0](/filings/0001740332-26-000018.md) | [48.0](/filings/0001740332-26-000025.md) |
| Selling, general and administrative | $m | [233](/filings/0001740332-24-000059.md) | [241 d](/filings/0001740332-26-000005.md) | [231](/filings/0001740332-25-000019.md) | [280](/filings/0001740332-25-000024.md) | [317](/filings/0001740332-25-000034.md) | [310 d](/filings/0001740332-26-000005.md) | [306](/filings/0001740332-26-000018.md) | [319](/filings/0001740332-26-000025.md) | [324](/filings/0001740332-25-000034.md) | [317 d](/filings/0001740332-26-000005.md) | [340](/filings/0001740332-26-000018.md) | [332](/filings/0001740332-26-000025.md) |
| Operating income | $m | [109](/filings/0001740332-24-000059.md) | [147 d](/filings/0001740332-26-000005.md) | [128](/filings/0001740332-25-000019.md) | [122](/filings/0001740332-25-000024.md) | [126](/filings/0001740332-25-000034.md) | [144 d](/filings/0001740332-26-000005.md) | [136](/filings/0001740332-26-000018.md) | [177](/filings/0001740332-26-000025.md) | [154](/filings/0001740332-25-000034.md) | [140 d](/filings/0001740332-26-000005.md) | [102](/filings/0001740332-26-000018.md) | [131](/filings/0001740332-26-000025.md) |
| Interest expense | $m | [16.0](/filings/0001740332-24-000059.md) | [15.0 d](/filings/0001740332-26-000005.md) | [13.0](/filings/0001740332-25-000019.md) | [15.0](/filings/0001740332-25-000024.md) | [27.0](/filings/0001740332-25-000034.md) | [26.0 d](/filings/0001740332-26-000005.md) | [25.0](/filings/0001740332-26-000018.md) | [24.0](/filings/0001740332-26-000025.md) | [37.0](/filings/0001740332-25-000034.md) | [49.0 d](/filings/0001740332-26-000005.md) | [47.0](/filings/0001740332-26-000018.md) | [46.0](/filings/0001740332-26-000025.md) |
| Income tax | $m | [16.0](/filings/0001740332-24-000059.md) | [19.0 d](/filings/0001740332-26-000005.md) | [30.0](/filings/0001740332-25-000019.md) | [29.0](/filings/0001740332-25-000024.md) | [24.0](/filings/0001740332-25-000034.md) | [22.0 d](/filings/0001740332-26-000005.md) | [9.0](/filings/0001740332-26-000018.md) | [87.0](/filings/0001740332-26-000025.md) | [(46.0)](/filings/0001740332-25-000034.md) | [20.0 d](/filings/0001740332-26-000005.md) | [17.0](/filings/0001740332-26-000018.md) | [69.0](/filings/0001740332-26-000025.md) |
| Net income | $m | [21.0](/filings/0001740332-24-000059.md) | [82.0 d](/filings/0001740332-26-000005.md) | [43.0](/filings/0001740332-25-000019.md) | [30.0](/filings/0001740332-25-000024.md) | [20.0](/filings/0001740332-25-000034.md) | [23.0 d](/filings/0001740332-26-000005.md) | [6.0](/filings/0001740332-26-000018.md) | [(825)](/filings/0001740332-26-000025.md) | [156](/filings/0001740332-25-000034.md) | [136 d](/filings/0001740332-26-000005.md) | [38.0](/filings/0001740332-26-000018.md) | [97.0](/filings/0001740332-26-000025.md) |
| Diluted EPS | $ per share | [0.14](/filings/0001740332-24-000059.md) | not reported | [0.29](/filings/0001740332-25-000019.md) | [0.19](/filings/0001740332-25-000024.md) | [0.07](/filings/0001740332-25-000034.md) | not reported | [(0.02)](/filings/0001740332-26-000018.md) | [(5.59)](/filings/0001740332-26-000025.md) | [0.85](/filings/0001740332-25-000034.md) | not reported | [0.17](/filings/0001740332-26-000018.md) | [0.51](/filings/0001740332-26-000025.md) |
| Basic EPS | $ per share | [0.14](/filings/0001740332-24-000059.md) | not reported | [0.29](/filings/0001740332-25-000019.md) | [0.19](/filings/0001740332-25-000024.md) | [0.07](/filings/0001740332-25-000034.md) | not reported | [(0.02)](/filings/0001740332-26-000018.md) | [(5.59)](/filings/0001740332-26-000025.md) | [0.88](/filings/0001740332-25-000034.md) | not reported | [0.17](/filings/0001740332-26-000018.md) | [0.52](/filings/0001740332-26-000025.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [368](/filings/0001740332-23-000027.md) | [636](/filings/0001740332-25-000010.md) | [603](/filings/0001740332-24-000045.md) | [413](/filings/0001740332-24-000053.md) | [531](/filings/0001740332-24-000059.md) | [692](/filings/0001740332-26-000005.md) | [577](/filings/0001740332-25-000019.md) | [753](/filings/0001740332-25-000024.md) | [345](/filings/0001740332-25-000034.md) | [661](/filings/0001740332-26-000025.md) | [438](/filings/0001740332-26-000018.md) | [549](/filings/0001740332-26-000025.md) |
| Current assets | $m | [2,615](/filings/0001740332-23-000027.md) | [2,743](/filings/0001740332-25-000010.md) | [2,677](/filings/0001740332-24-000045.md) | [2,884](/filings/0001740332-24-000053.md) | [3,037](/filings/0001740332-24-000059.md) | [3,172](/filings/0001740332-26-000005.md) | [3,061](/filings/0001740332-25-000019.md) | [3,392](/filings/0001740332-25-000024.md) | [3,072](/filings/0001740332-25-000034.md) | [3,358](/filings/0001740332-26-000025.md) | [3,174](/filings/0001740332-26-000018.md) | [3,825](/filings/0001740332-26-000025.md) |
| Total assets | $m | [6,459](/filings/0001740332-23-000027.md) | [6,645](/filings/0001740332-25-000010.md) | [6,520](/filings/0001740332-24-000045.md) | [7,984](/filings/0001740332-24-000053.md) | [8,135](/filings/0001740332-24-000059.md) | [8,199](/filings/0001740332-26-000005.md) | [8,074](/filings/0001740332-25-000019.md) | [8,515](/filings/0001740332-25-000024.md) | [8,188](/filings/0001740332-25-000034.md) | [8,433](/filings/0001740332-26-000025.md) | [8,207](/filings/0001740332-26-000018.md) | [8,781](/filings/0001740332-26-000025.md) |
| Current liabilities | $m | [1,467](/filings/0001740332-23-000027.md) | [1,525](/filings/0001740332-25-000010.md) | [1,385](/filings/0001740332-24-000045.md) | [1,594](/filings/0001740332-24-000053.md) | [1,672](/filings/0001740332-24-000059.md) | [1,790](/filings/0001740332-26-000005.md) | [1,578](/filings/0001740332-25-000019.md) | [3,382](/filings/0001740332-25-000024.md) | [1,632](/filings/0001740332-25-000034.md) | [1,755](/filings/0001740332-26-000025.md) | [1,531](/filings/0001740332-26-000018.md) | [1,721](/filings/0001740332-26-000025.md) |
| Total liabilities | $m | [3,814](/filings/0001740332-23-000027.md) | [3,896](/filings/0001740332-25-000010.md) | [3,751](/filings/0001740332-24-000045.md) | [4,690](/filings/0001740332-24-000053.md) | [4,781](/filings/0001740332-24-000059.md) | [4,890](/filings/0001740332-26-000005.md) | [4,727](/filings/0001740332-25-000019.md) | [5,901](/filings/0001740332-25-000024.md) | [5,417](/filings/0001740332-25-000034.md) | [5,516](/filings/0001740332-26-000025.md) | [5,285](/filings/0001740332-26-000018.md) | [5,775](/filings/0001740332-26-000025.md) |
| Long-term debt | $m | [1,397](/filings/0001740332-23-000027.md) | [1,396](/filings/0001740332-25-000010.md) | [1,394](/filings/0001740332-24-000045.md) | [1,979](/filings/0001740332-24-000053.md) | [1,983](/filings/0001740332-24-000059.md) | [1,983](/filings/0001740332-26-000005.md) | [1,983](/filings/0001740332-25-000019.md) | [1,983](/filings/0001740332-25-000024.md) | [3,169](/filings/0001740332-25-000034.md) | [3,167](/filings/0001740332-26-000025.md) | [3,165](/filings/0001740332-26-000018.md) | [3,560](/filings/0001740332-26-000025.md) |
| Current portion of debt | $m | [12.0](/filings/0001740332-23-000027.md) | [12.0](/filings/0001740332-25-000010.md) | [12.0](/filings/0001740332-24-000045.md) | [12.0](/filings/0001740332-24-000053.md) | [6.0](/filings/0001740332-24-000059.md) | [6.0](/filings/0001740332-26-000005.md) | [8.0](/filings/0001740332-25-000019.md) | [8.0](/filings/0001740332-25-000024.md) | [20.0](/filings/0001740332-25-000034.md) | [18.0](/filings/0001740332-26-000025.md) | [18.0](/filings/0001740332-26-000018.md) | [18.0](/filings/0001740332-26-000025.md) |
| Shareholders' equity | $m | [2,645](/filings/0001740332-24-000059.md) | [2,749](/filings/0001740332-26-000005.md) | [2,769](/filings/0001740332-25-000024.md) | [3,294](/filings/0001740332-25-000034.md) | [3,354](/filings/0001740332-25-000034.md) | [3,309](/filings/0001740332-26-000025.md) | [3,347](/filings/0001740332-26-000025.md) | [2,614](/filings/0001740332-26-000025.md) | [2,771](/filings/0001740332-25-000034.md) | [2,917](/filings/0001740332-26-000025.md) | [2,922](/filings/0001740332-26-000025.md) | [3,006](/filings/0001740332-26-000025.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [60.0 d](/filings/0001740332-24-000059.md) | [263 d](/filings/0001740332-26-000005.md) | [2.0](/filings/0001740332-25-000019.md) | [92.0 d](/filings/0001740332-25-000024.md) | [147 d](/filings/0001740332-25-000034.md) | [203 d](/filings/0001740332-26-000005.md) | [(65.0)](/filings/0001740332-26-000018.md) | [200 d](/filings/0001740332-26-000025.md) | [(1,571) d](/filings/0001740332-25-000034.md) | [299 d](/filings/0001740332-26-000005.md) | [(145)](/filings/0001740332-26-000018.md) | [148 d](/filings/0001740332-26-000025.md) |
| Capital expenditure | $m | [25.0 d](/filings/0001740332-24-000059.md) | [31.0 d](/filings/0001740332-26-000005.md) | [21.0](/filings/0001740332-25-000019.md) | [15.0 d](/filings/0001740332-25-000024.md) | [22.0 d](/filings/0001740332-25-000034.md) | [22.0 d](/filings/0001740332-26-000005.md) | [31.0](/filings/0001740332-26-000018.md) | [20.0 d](/filings/0001740332-26-000025.md) | [28.0 d](/filings/0001740332-25-000034.md) | [37.0 d](/filings/0001740332-26-000005.md) | [36.0](/filings/0001740332-26-000018.md) | [29.0 d](/filings/0001740332-26-000025.md) |
| Share repurchases | $m | not reported | [13.0 d](/filings/0001740332-26-000005.md) | [1.0](/filings/0001740332-24-000045.md) | not reported | not reported | [0.0 d](/filings/0001740332-26-000005.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [149](/filings/0001740332-23-000027.md) | [149](/filings/0001740332-24-000045.md) | [149](/filings/0001740332-24-000053.md) | [148](/filings/0001740332-24-000059.md) | [148](/filings/0001740332-25-000019.md) | [149](/filings/0001740332-25-000024.md) | [149](/filings/0001740332-25-000034.md) | [148](/filings/0001740332-26-000018.md) | [149](/filings/0001740332-26-000025.md) | [154](/filings/0001740332-25-000034.md) | [155](/filings/0001740332-26-000018.md) | [154](/filings/0001740332-26-000025.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 151,847,378 at 2026-08-05, from the cover of the [10-Q filed 2026-08-12](/filings/0001740332-26-000025.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.